143 related articles for article (PubMed ID: 35080069)
1. Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
Nagumo Y; Onozawa M; Kojima T; Terada N; Shiota M; Mitsuzuka K; Yasumoto H; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Saito T; Yokomizo A; Kohei N; Tabata KI; Takahashi A; Sugimoto M; Kitamura H; Kamoto T; Nishiyama H;
Int J Urol; 2022 May; 29(5):398-405. PubMed ID: 35080069
[TBL] [Abstract][Full Text] [Related]
2. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute.
Miyazawa Y; Sekine Y; Arai S; Oka D; Nakayama H; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
In Vivo; 2021; 35(1):373-384. PubMed ID: 33402486
[TBL] [Abstract][Full Text] [Related]
4. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
Yoshida T; Kawai T; Hagiwara K; Yanagida K; Noda M; Tokura Y; Yoshimura I; Kaneko T; Nakagawa T
Jpn J Clin Oncol; 2024 Apr; 54(4):498-503. PubMed ID: 38251778
[TBL] [Abstract][Full Text] [Related]
5. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B
Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
7. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
8. Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.
Onozawa M; Akaza H; Hinotsu S; Oya M; Ogawa O; Kitamura T; Suzuki K; Naito S; Namiki M; Nishimura K; Hirao Y; Tsukamoto T
Cancer Med; 2018 Oct; 7(10):4893-4902. PubMed ID: 30151999
[TBL] [Abstract][Full Text] [Related]
9. Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Hamano I; Okamoto T; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Int J Urol; 2020 Jul; 27(7):610-617. PubMed ID: 32418347
[TBL] [Abstract][Full Text] [Related]
10. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Shiota M; Terada N; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Mizowaki T; Kamoto T; Kojima T; Kitamura H; Sugimoto M; Nishiyama H; Eto M;
Cancer Sci; 2021 Apr; 112(4):1524-1533. PubMed ID: 33159829
[TBL] [Abstract][Full Text] [Related]
11. Advantages of total androgen blockade in the treatment of advanced prostate cancer.
Geller J; Albert J; Vik A
Semin Oncol; 1988 Apr; 15(2 Suppl 1):53-61. PubMed ID: 3285484
[TBL] [Abstract][Full Text] [Related]
12. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.
Shiota M; Terada N; Kitamura H; Kojima T; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Sugimoto M; Mizowaki T; Kamoto T; Nishiyama H; Eto M;
Cancer Sci; 2021 Sep; 112(9):3616-3626. PubMed ID: 34145921
[TBL] [Abstract][Full Text] [Related]
13. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
14. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
[TBL] [Abstract][Full Text] [Related]
15. Bicalutamide dosages used in the treatment of prostate cancer.
Kolvenbag GJ; Nash A
Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy combined with androgen-deprivation therapy in high-volume metastatic hormone sensitive prostate cancer: a short-term efficacy and safety analysis].
Xu PH; Shen YJ; Xiao WJ; Lin GW; Qin XJ; Zhu Y; Dai B; Ye DW
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):418-421. PubMed ID: 31142065
[No Abstract] [Full Text] [Related]
17. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
18. Intermittent versus continuous androgen deprivation in prostate cancer.
Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
[TBL] [Abstract][Full Text] [Related]
19. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
20. Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
Okamoto T; Noro D; Hatakeyama S; Narita S; Mitsuzuka K; Sakurai T; Kawamura S; Hoshi S; Shimoda J; Tanaka T; Kawaguchi T; Ishidoya S; Ito A; Tsuchiya N; Habuchi T; Ohyama C
BMC Cancer; 2021 May; 21(1):605. PubMed ID: 34034691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
